Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | PTGER3 | P43115 | 8/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 7/20 | 0.49 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.49 |
| ▸ | PTGFR | P43088 | 3/20 | 0.49 |
| ▸ | PTGIR | P43119 | 2/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3685251 | 1.00 | EGFR (0.53) | EGFRPTGER3PTGER2PTGDRPTGER4 | |
| SCHEMBL20531196 | 0.85 | PTGS1 (0.46) | EGFRPTGER3PTGER2PTGDRPTGER4 | |
| SCHEMBL9613260 | 0.85 | ESR1 (0.55) | EGFRPTGER3PTGER2PTGDRPTGER4 | |
| SCHEMBL8575027 | 0.83 | EIF2AK2 (0.47) | EGFRPTGER3PTGER2PTGDRPTGER4 | |
| SCHEMBL9390825 | 0.83 | PTGER3 (0.52) | EGFRPTGER3PTGER2PTGDRPTGER4 | |
| SCHEMBL7134072 | 0.83 | EGFR (0.57) | EGFRPTGER3PTGER2PTGDRPTGER4 | |
| SCHEMBL9447849 | 0.83 | MIF (0.60) | EGFRPTGER3PTGER2PTGDRPTGER4 | |
| SCHEMBL1174443 | 0.83 | NPSR1 (0.49) | EGFRPTGER3PTGER2PTGDRPTGER4 | |
| SCHEMBL1174440 | 0.83 | NPSR1 (0.49) | EGFRPTGER3PTGER2PTGDRPTGER4 | |
| SCHEMBL10350184 | 0.83 | MIF (0.60) | EGFRPTGER3PTGER2PTGDRPTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795310-B2 | Methods and reagents for the treatment of metabolic disorders | COMBINATORX, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-1781303-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | COMBINATORX INC (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1781303-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | CombinatoRx, Incorporated (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060069161-A1 | Methods and reagents for the treatment of metabolic disorders | COMBINATORX, INC. (US) | 2006-03-30 | — | — | US | disclosed |
| WO-2006004803-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | COMBINATORX, INCORPORATED (US) | 2006-01-12 | — | — | WO | disclosed |
| US-4026896-A | ANTIALLERGENS | KISSEI YAKUHIN KOGYO KABUSHIKI KAISHA (KISSEI PHARMACEUTICAL CO. LTD.) (JA) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069161-A1 | Methods and reagents for the treatment of metabolic disorders | LIPC, PNLIP, GOT2 | EGFR 3982/4885PTGER3 3388/4885PTGER2 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.